Precision Biosciences Inc.

DTIL Nasdaq SEC CIK 1357874
Follow Precision Biosciences Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $0 −100% vs same quarter last year
Net income −$7.6M +65.2% vs same quarter last year
EPS, diluted −$0.28 +84.8% vs same quarter last year
Operating cash flow −$15.1M +0.9% vs same quarter last year
Revenue by quarter
$638K
$29K
$18K
$13K
$34.2M
$10.8M
$0
$0
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income9 fiscal years
  • Revenue
  • Net income
−$200M−$100M$0$100M$200MFY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$34.3M−$45.7M
FY24$68.7M$7.2M
FY23$48.7M−$61.3M
FY22$25.1M−$111.6M
FY21$115.5M−$30.6M
FY20$24.3M−$109M
FY19$22.2M−$92.9M
FY18$10.9M−$46M
FY17--
MarginsShare of revenue
  • Operating margin
  • Net margin
−600%−400%−200%0%200%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−152.2%−133.4%
FY24−38.1%10.4%
FY23−89.8%−125.8%
FY22−248.3%−444.8%
FY21−34.1%−26.5%
FY20−452.2%−448.9%
FY19−392.1%−417.6%
FY18−440.2%−423%
FY17--
Free cash flowOperating cash flow minus capital expenditure
−$100M−$75M−$50M−$25M$0FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$65.9M
FY24−$58.7M
FY23−$86.1M
FY22−$49.1M
FY21−$15.9M
FY20−$92.4M
FY19−$95.7M
FY18−$66M
FY17-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Precision Biosciences
  • Healthcare median
−600%−400%−200%0%200%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearPrecision BiosciencesHealthcare median
FY25−133.4%−30.6%
FY2410.4%−47%
FY23−125.8%−58%
FY22−444.8%−80.4%
FY21−26.5%−71.8%
FY20−448.9%−62.2%
FY19−417.6%−46.2%
FY18−423%−49.6%
FY17-−45.9%